Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen R&D’s Immunology Unit Grounded In Translational Thinking

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

J&J finished pulling together its disparate R&D efforts under the Janssen name in December, with a distinctive translational thread running through the entire soup-to-nuts operation. The immunology unit showcases the firm’s success with this method – the understanding of a psoriasis mechanism gained in the clinic looped back to inform research on several next generation therapies and a very broad Remicade label.

You may also be interested in...



J&J’s Anti-IL-23 Guselkumab Phase III-Ready After Solid Psoriasis Results

Specific interleukin-23 blocker meets primary endpoint in Phase IIb dose-ranging study, paving the way for pivotal trials.

J&J’s Anti-IL-23 Guselkumab Phase III-Ready After Solid Psoriasis Results

Specific interleukin-23 blocker meets primary endpoint in Phase IIb dose-ranging study, paving the way for pivotal trials.

How Biologics Are Powering J&J’s Resurgent Drug Business: An Interview with Jay Siegel

After well-publicized problems in Johnson & Johnson’s devices and consumer health divisions, in the words of a recent Deutsche Bank research note, “It’s pharmaceuticals’ time to shine.” Indeed, the diversified health care company expects to file 11 new drugs and over 31 line extensions by 2015. Though growth is now expected from J&J’s pharma business, less well understood is the role of biologics, both marketed and near to market, in driving that expansion and J&J’s increased focus on specialty products.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel